inHEART, a medical device company specializing in AI-driven digital twin technology for the heart, announced a noteworthy milestone with the receipt of FDA 510(k) clearance for its latest AI software module. This innovative module facilitates fully automated segmentation of CT images, revolutionizing the creation of 3D cardiac models and expediting delivery to physicians.

Previously available to clinicians in the EU, the FDA clearance now enables inHEART to introduce its advanced AI-driven solution to hospitals across the United States. This breakthrough marks a key advancement in cardiac imaging technology, allowing for unparalleled speed and efficiency in delivering vital insights to healthcare professionals.

Todor Jeliaskov, President, and CEO of inHEART, emphasized the transformative impact of this milestone, stating, "The addition of AI automation is an important milestone as it allows us to optimize the expertise of our team and deliver our solution within hours to physicians. Our mission is to make world-class cardiac imaging expertise available to all physicians to optimize treatment strategies, improve clinical outcomes, and treat patients in a timely manner."

The inHEART solution represents a paradigm shift in cardiac ablation procedures by creating highly detailed, interactive 3D models of the heart using proprietary segmentation algorithms. These models, generated from preprocedural CT and/or MR images, empower physicians to tailor treatment strategies based on each patient's unique cardiac anatomy, enhancing pre-procedural planning and integration into electroanatomic mapping systems.

With the integration of the new AI module, inHEART aims to significantly streamline the delivery of its solution to physicians, thereby enhancing workflow efficiency and patient care. Early clinical evaluations of inHEART have demonstrated remarkable potential, including a 60 percent reduction in VT (ventricular tachycardia) procedure times compared to conventional approaches, from 5 hours to less than 2 hours. Moreover, image-guided ablations utilizing inHEART have shown a 38 percent reduction in VT recurrence rates compared to conventional strategies, underscoring the clinical benefits of this cutting-edge technology.

The FDA clearance of inHEART's AI software module indicates a new era in cardiac imaging, paving the way for enhanced treatment outcomes, improved patient experiences, and broader accessibility to advanced healthcare solutions across the United States.